- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Dr Shah on Remaining Unmet Needs in RCC After Frontline IO Combinations
Neil J. Shah, MBBS, discusses unmet needs for patients with RCC receiving immune-oncology–based combinations in the frontline setting.
- 2x
- 1.75x
- 1.5x
- 1.25x
- 1x, selected
- 0.75x
- 0.5x
- Chapters
- descriptions off, selected
- captions settings, opens captions settings dialog
- captions off, selected
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
End of dialog window.
This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.
Neil J. Shah, MBBS, assistant attending physician, genitourinary oncologist, Memorial Sloan Kettering Cancer Center, discusses unmet needs for patients with renal cell carcinoma (RCC) receiving immune-oncology (IO)–based combinations in the frontline setting.
Most patients with advanced RCC will receive an IO/IO or IO/TKI combination in the frontline setting, but unmet needs remain for these patients. Shah and coauthors presented a real-world study during 2024 Kidney Cancer Research Summit, which demonstrated that patients with RCC who received various IO/IO and IO/TKI combinations all experienced similar outcomes, and there is limited overall survival in the post-IO/IO and -IO/TKI setting, underscoring the need for the development of more novel therapies in the space.
Related Content:
